Market News & Analysis

Top Story

Equity brief: Europe sees weak earnings in bag, hence the drag

Stock market snapshot as of [11/7/2019 4:04 PM]

  • The day after the Fed wafted—with Powell-comments and FOMC minutes— a confirmation that it remains highly likely to cut by 25 basis points in July, European stocks still aren’t as cheered as those in the U.S. and Asia
  • Both Dow and S&P 500 opened with highly significant, albeit largely symbolic moves to the ‘psychological’ levels of 27,000 and 3,000 respectively. The jury’s out as to whether their hesitant rallies can keep the markets above those round numbers into the close. In context though, they have marked investors’ positive response to the Fed’s signal nonetheless
  • As per a day ago, European markets contrast with a more mixed flavour. DAX, CAC and FTSE post anaemic gains or small losses. FTSE MIB continues its post-populism recovery, rising 0.6%. This after ECB minutes showed a strong consensus for cuts this year. Germany’s upwardly revised inflation data that lifts the euro (and a point against rate cuts) may be a bone of contention. The main drag however, remains earnings pessimism. This matches sentiment on forthcoming results Stateside, but unlike on Wall Street, there’s a sense that European large-caps may struggle to outpace even the low-ball forecasts they’ve been handed. With the broad STOXX 600 up a decent 15% for the year after last week’s 2019 high, plus with policy stimulus undefined, such sentiment may only point the market lower in the second half

Corporate News

  • Illustrating Thursday’s lack of enthusiasm, Europe’s large-cap gainer was Reckitt Benckiser, rising around 2.5% near close after agreeing a $1.4bn fine. The penalty is linked to formerly owned opioid maker, Indivior. That mid-cap itself rose as much as 40%. Neither are entirely out of the woods, lawsuit-wise
  • Among U.S. shares, another notable 2019 laggard, insurer United Health also took the spotlight with a 5% gain whilst select rival insurers also rallied. Pharma and biotech stocks mostly went the opposite direction. The White House has just pulled the plug on a proposed drug rebate overhaul but there’s speculation that Washington may look to target makers of high-priced drugs instead
  • Retail is edging back into view in a negative way. Both GameStop and Bed Bath & Beyond fell hard, after a necessary plan to sell new shares and after Wall Street turned sceptical on forecasts, respectively

Upcoming economic highlights


This report is intended for general circulation only. It should not be construed as a recommendation, or an offer (or solicitation of an offer) to buy or sell any financial products. The information provided does not take into account your specific investment objectives, financial situation or particular needs. Before you act on any recommendation that may be contained in this report, independent advice ought to be sought from a financial adviser regarding the suitability of the investment product, taking into account your specific investment objectives, financial situation or particular needs.

GAIN Capital Singapore Pte. Ltd., may distribute reports produced by its respective foreign entities or affiliates within the GAIN Capital group of companies or third parties pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed to a person in Singapore who is not an accredited investor, expert investor or an institutional investor (as defined in the Securities Futures Act), GAIN Capital Singapore Pte. Ltd. accepts legal responsibility to such persons for the contents of the report only to the extent required by law. Singapore recipients should contact GAIN Capital Singapore Pte. Ltd. at 6826 9988 for matters arising from, or in connection with the report.

In the case of all other recipients of this report, to the extent permitted by applicable laws and regulations neither GAIN Capital Singapore Pte. Ltd. nor its associated companies will be responsible or liable for any loss or damage incurred arising out of, or in connection with, any use of the information contained in this report and all such liability is hereby expressly disclaimed. No representation or warranty is made, express or implied, that the content of this report is complete or accurate.

GAIN Capital Singapore Pte. Ltd. is not under any obligation to update this report.

Trading CFDs and FX on margin carries a high level of risk that may not be suitable for some investors. Consider your investment objectives, level of experience, financial resources, risk appetite and other relevant circumstances carefully. The possibility exists that you could lose some or all of your investments, including your initial deposits. If in doubt, please seek independent expert advice. Visit for the complete Risk Disclosure Statement.

Important Notice:

Cryptocurrencies are not legal tender currency and trading of derivatives on Cryptocurrencies are currently not covered under any regulatory regime in Singapore. Consequently, investors should be aware they do not have protection under the Securities and Futures Act (Cap. 289). Please ensure that you are fully aware of the risks.